




# Pneumococcal Vaccines Work Group Considerations and Next Steps

**Miwako Kobayashi, MD, MPH**

Pneumococcal Vaccines Work Group  
Advisory Committee on Immunization Practices  
February 22, 2023

## Proposed Policy Questions

- Should PCV20 be recommended as an option for pneumococcal conjugate vaccination according to currently recommended dosing and schedules, for U.S. children aged <2 years?
- Should PCV20 without PPSV23 be recommended as an option for pneumococcal vaccination for U.S. children aged 2–18 years with underlying medical conditions that increase the risk of pneumococcal disease?



## Additional Considerations

- Cost-effectiveness analysis will be performed to assess:
  - **Incremental benefit of PPSV23 use** in addition to PCV20 in children aged 2–18 years with underlying medical conditions.
  - **Incremental benefit of PCV20 use** in children who completed the recommended PCV series with either PCV13 or PCV15.

# **Pneumococcal Disease Risk in Children with Underlying Medical Conditions**

Asthma, Chronic Kidney Disease, Chronic Liver Disease

## Specific Questions Being Considered by the Work Group

- Are children with asthma at increased risk of pneumococcal disease **regardless of high-dose oral corticosteroid use?**
- Are children with **chronic liver disease** at increased risk of pneumococcal disease?
- Are children with **chronic kidney disease of any stage** at increased risk of pneumococcal disease?

# Differences in the Indications for Children vs Adults with Asthma

- **Pediatric** recommendation<sup>1,2</sup>:
  - Including asthma **if treated with high-dose oral corticosteroid therapy**
- **Adult** recommendation<sup>3,4</sup>:
  - Includes chronic obstructive pulmonary disease, emphysema, and **asthma**

1. [Nuorti et al. MMWR RR 2010](#)
2. [Kobayashi et al. MMWR 2022. 71\(37\); 1174–1181](#)
3. [Matanock et al. MMWR 2019](#)
4. [Kobayashi et al. MMWR 2022. 71\(4\); 109–117](#)

# Risk-Based Pneumococcal Vaccine Recommendations

	Children	Adults
Alcoholism	Grey bar	Yellow background
Chronic heart disease	Yellow background	Yellow background
Chronic lung disease	Yellow background	Yellow background
Chronic liver disease	Grey bar	Yellow background
Cigarette smoking	Grey bar	Yellow background
Diabetes mellitus	Yellow background	Yellow background
Cerebrospinal fluid leak	Yellow background	Yellow background
Cochlear implant	Yellow background	Yellow background
Chronic renal failure or nephrotic syndrome	Yellow background	Yellow background
Congenital or acquired asplenia, or splenic dysfunction	Yellow background	Yellow background
Congenital or acquired immunodeficiency	Yellow background	Yellow background
Diseases and conditions treated with immunosuppressive drugs or radiation therapy	Yellow background	Yellow background
HIV infection	Yellow background	Yellow background
Sickle cell disease or other hemoglobinopathies	Yellow background	Yellow background
Solid organ transplant	Yellow background	Yellow background

**Should we add “chronic liver disease” as part of pediatric risk-based recommendation?**

# Risk-Based Pneumococcal Vaccine Recommendations

	Children	Adults
Alcoholism	Grey bar	
Chronic heart disease		
Chronic lung disease		
Chronic liver disease	Grey bar	
Cigarette smoking	Grey bar	
Diabetes mellitus		
Cerebrospinal fluid leak		
Cochlear implant		
<b>Chronic renal failure</b> or nephrotic syndrome		<div style="border: 2px solid red; padding: 10px;"> <p><b>The intent has been to provide additional protection for those on dialysis or about to be on dialysis</b></p> <p><b>→ Should the risk-based recommendations be expanded to all CKD stages?</b></p> </div>
Congenital or acquired asplenia, or splenic dysfunction		
Congenital or acquired immunodeficiency		
Diseases and conditions treated with immunosuppressive drugs or radiation therapy		
HIV infection		
Sickle cell disease or other hemoglobinopathies		
Solid organ transplant		

# Work Group Next Steps

# Work Group Next Steps

- Review of evidence and Work Group interpretation of remaining EtR domains (**Values, Acceptability, Resource Use, Feasibility**)
- Review findings from cost-effectiveness analyses (CDC and other groups)
- Draft policy options on PCV20 use in U.S. children for consideration by the committee

## Questions for the Committee

- **Does the Committee agree with the policy questions being considered by the Work Group?**
- **Are there additional data the Committee would like to see before deciding on policy options for a vote?**



For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

